Literature DB >> 10479493

Prognostic significance of DNA ploidy in endometrial cancer.

D M Larson1, R Berg, G Shaw, B R Krawisz.   

Abstract

OBJECTIVE: The aim of this study was to analyze the prognostic significance of DNA ploidy in patients with endometrial cancer.
METHODS: Between October 1988 and January 1997, DNA ploidy was determined prospectively in 208 women who were staged surgically by a standard protocol that included pelvic and para-aortic lymphadenectomy. Median follow-up was 48 months.
RESULTS: Diploid tumors were identified in 154 (74%) patients and aneuploid tumors in 54 (26%). Patients with aneuploid tumors had a significantly higher prevalence of metastases to the cervix, adnexa, and omentum, malignant pelvic cytology, and advanced surgical stage. Patients with aneuploid tumors had a 4.5 times higher prevalence of pelvic lymph node metastases and a 5.8 times higher prevalence of para-aortic lymph node metastases. A significantly higher proportion of patients with aneuploid tumors was diagnosed with recurrent or progressive endometrial cancer (22.2 versus 6.5%, P = 0.002). Patients with aneuploid tumors had a significantly lower rate of survival from cancer death (P = 0.038) with 83% versus 94% surviving 5 years.
CONCLUSION: Patients with aneuploid tumors are at high risk for lymph node metastases and should be surgically staged, including pelvic and para-aortic lymphadenectomy. Aneuploidy confers a risk for endometrial cancer death and these patients should be candidates for clinical trials evaluating treatment following surgery. Copyright 1999 Academic Press.

Entities:  

Mesh:

Year:  1999        PMID: 10479493     DOI: 10.1006/gyno.1999.5498

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  1 in total

1.  DNA ploidy in curettage specimens identifies high-risk patients and lymph node metastasis in endometrial cancer.

Authors:  T S Njølstad; J Trovik; T S Hveem; M L Kjæreng; W Kildal; M Pradhan; J Marcickiewicz; S Tingulstad; A C Staff; H K Haugland; R Eraker; K Oddenes; J A Rokne; J Tjugum; M S Lode; F Amant; H M Werner; H B Salvesen; H E Danielsen
Journal:  Br J Cancer       Date:  2015-04-21       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.